• 91073+ Medical Conferences
  • 207 Specialties
  • 14381 Organizers
  • 111211 Speakers
  • 147 Countries
  • 3624 Cities
30358+
CME Conference Registrations Sold

SEARCH NEWS
Or

MONTHLY BRIEFINGS - Jan 2018


Losartan May Improve Endothelial Function in Marfan Syndrome

Losartan May Improve Endothelial Function in Marfan Syndrome

Tue, Feb 13, 2018

TUESDAY, Feb. 13, 2018 (HealthDay News) -- The therapeutic significance of losartan in Marfan syndrome (MFS) may lie in its ability to activate protective endothelial function, not in its angiotensin II (AngII) receptor type 1 (ATR1) inhibition, according to a study published online Feb. 9 in the American Journal of Pathology.

In an attempt to preserve protective ATR2 signaling, Stephanie L. Sellers, from the University of British Columbia in Vancouver, Canada, and colleagues generated MFS mice lacking ATR1a expression.

The researchers found that the MFS/ATR1a-null mice showed unabated aortic root enlargement and remained responsive to losartan, despite being hypotensive and resistant to AngII vasopressor effects. Nitric oxide synthase (NOS) inhibition renders losartan therapeutically inactive, while aortic root dilation was blocked in multiple transgenic and pharmacologic models of endothelial NOS activation by correcting extracellular signal-regulated kinase signaling. Losartan can increase endothelial NO release in the absence of Ang II in vitro, and it can correct MFS NO levels in vivo.

"Our data suggest that increased protective endothelial function, rather than ATR1 inhibition or blood pressure lowering, might be of therapeutic significance in preventing aortic root disease in MFS," the authors write.

Abstract
Full Text